Nisa Leung is a Managing Partner of Qiming Venture Partners, leading its health care investments.
She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Venus MedTech, Nurotron, dMed, CanSino Biologics (HKSE: 6185), New Horizon Bio, Berry Oncology Insilico Medicine among others. Her other investments include Aeonmed Medical, Berry Genomics (SZSE:000710), CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (acquired by JSR Life Sciences), Goodwill Information Technology, Novast Pharmaceuticals, Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen, Cure Genetics, SinoCell Tech, Apollomics, Sino United, Schrodinger and Jacobio among others.
Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, named Top 3 Best Female Venture Capitalist in China by Forbes in 2018 and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.
She is currently a visiting lecturer at Harvard Law School, a founding vice chair of PhIRDA Investment Committee, Committee member of Hong Kong Innovation and Technology Development and Re-Industrialization and member of Stanford Graduate School of Business Advisory Council. She also serves on the Board of Trustees of the Hotchkiss School and is a board member of the Hong Kong Palace Museum.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ: SCLN), U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park and was previously with Softbank/Mobius Venture Capital.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University.